FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

10 results

acetylcysteine
(Acetylcysteine)
Somerset Therapeutics, LLC
Usage: Acetylcysteine solution, USP is indicated as adjuvant therapy for abnormal mucous secretions in chronic and acute bronchopulmonary diseases, pulmonary complications of cystic fibrosis, tracheostomy care, surgical pulmonary complications, anesthetic use, post-traumatic chest conditions, atelectasis due to mucous obstruction, and diagnostic bronchial studies.
alyftrek
(vanzacaftor, tezacaftor, and deutivacaftor)
Vertex Pharmaceuticals Incorporated
Usage: ALYFTREK is indicated for treating cystic fibrosis in patients aged 6 and older with at least one F508del mutation or another responsive CFTR mutation. An FDA-cleared CF mutation test is recommended if the patient's genotype is unknown.
cayston
(aztreonam)
Gilead Sciences, Inc.
Usage: CAYSTON® is indicated for improving respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. It is not established for use in patients under 7, those with FEV1 <25% or >75%, or those colonized with Burkholderia cepacia. It should only be used in confirmed Pseudomonas infections.
kalydeco
(ivacaftor)
Vertex Pharmaceuticals Incorporated
Usage: KALYDECO is indicated for the treatment of cystic fibrosis in patients aged 1 month and older with at least one responsive CFTR gene mutation. If the mutation is unknown, an FDA-cleared test should be used to identify it.
orkambi
(lumacaftor and ivacaftor)
Vertex Pharmaceuticals Incorporated
Usage: ORKAMBI is indicated for the treatment of cystic fibrosis in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. Efficacy and safety have not been established in other CF genotypes. Testing for the mutation is recommended if unknown.
pulmozyme
(dornase alfa)
Genentech, Inc.
Usage: PULMOZYME® is indicated for managing cystic fibrosis in pediatric and adult patients to improve pulmonary function and reduce the risk of respiratory tract infections requiring parenteral antibiotics in those with an FVC ≥ 40% of predicted, when used alongside standard therapies.
symdeko
(Tezacaftor and Ivacaftor)
Vertex Pharmaceuticals Incorporated
Usage: SYMDEKO is indicated for treating cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del mutation or have a responsive CFTR mutation, as determined by in vitro data or clinical evidence. Testing is recommended for patients with an unknown genotype.
tobramycin
(Tobramycin)
Ritedose Pharmaceuticals, LLC
Usage: Tobramycin inhalation solution is indicated for managing cystic fibrosis in adults and pediatric patients aged 6 and older with Pseudomonas aeruginosa. Its safety and efficacy are not established for those under 6, with specific FEV1 limitations, or colonized with Burkholderia cepacia.
tobramycin inhalation
(tobramycin inhalation)
Prasco, LLC
Usage: Tobramycin Inhalation Solution is indicated for managing cystic fibrosis in patients with Pseudomonas aeruginosa. Its safety and efficacy are not established in individuals under six years, those with FEV1 less than 40% or greater than 80%, or patients colonized with Burkholderia cepacia.
trikafta
(Elexacaftor, Tezacaftor, and Ivacaftor)
Vertex Pharmaceuticals Incorporated
Usage: TRIKAFTA is indicated for treating cystic fibrosis in patients aged 2 years and older with at least one F508del mutation in the CFTR gene, or other responsive CFTR mutations verified by clinical or laboratory data. An FDA-cleared CF mutation test is recommended if the genotype is unknown.

Medications for Cystic Fibrosis

acetylcysteine

alyftrek

cayston

kalydeco

orkambi

pulmozyme

symdeko

tobramycin

tobramycin inhalation

trikafta